
Vali oma silt
näidatakse otse viaalilOstarine (MK-2866)
SARMs
- Saadetakse Saksamaalt
Tellimus
- DHL koos jälgimisega
- Diskreetne pakend
4.6 5-st Trustpilotis73 arvustust
Otsitud ka nimega: Ostarin
Lühidalt
Ostarine (MK-2866) arvudes
Põhinäitajad meie leksikonist. Lohista punkti mööda kõverat, et näha, kui palju jääb pärast ühte annust arvutuslikult alles.
Täielik leksikoni artikkelHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~24 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
approx.24hours
- Class
- SARMnon-steroidal
- Use
- Oraldaily
- Sizes
- 25 mg1 size in the shop
What studies show
All 2 sources in the lexicon- Dalton et al., Journal of Cachexia, Sarcopenia and Muscle, 2011
Phase 2 study of enobosarm against muscle wasting in cancer patients (opens in a new tab)
Dobs et al., The Lancet Oncology, 2013
Arvustused
Mida kliendid ütlevad
Ainult päris tellimused, milles oli Ostarine (MK-2866).
Kõik arvustusedOstarine (MK-2866) jaoks pole veel laborianalüüsi. Hääleta selle pooltLase ise testida, meie maksame pooleKõik laborianalüüsid
Teadmised
Kõik teemal Ostarine (MK-2866)
Üksikasjalik teave tuleb peagi.
What is ostarine?
Ostarine, also enobosarm or MK-2866, is a non-steroidal modulator of the androgen receptor (SARM). It was developed against muscle wasting and is meant to act mainly in muscle and bone. It is not approved, the highest stage was phase 3.
What did the study in healthy older adults show?
120 men over 60 and postmenopausal women received placebo or one of four levels for 12 weeks. At the higher level fat-free mass rose by 1.3 kg more than on placebo, fat fell by about 0.6 kg and weight stayed the same. Stair climbing got faster and insulin resistance fell by 27.5 percent. Side effects were as frequent as on placebo.
And in cancer patients?
In a phase 2 trial with 159 cancer patients with weight loss median fat-free mass rose by 1.5 kg (lower level) and 1.0 kg (higher level), on placebo by 0.02 kg. According to the trial the most common serious events were not related to the drug.
What happens to blood lipids and hormones?
HDL cholesterol fell by 17 and 27 percent. The binding protein SHBG fell by 61 percent in men and 80 percent in women. Total testosterone fell in men as well. Free testosterone did not change significantly.
What did the highest study dose show?
A trial in 136 women with advanced breast cancer had two levels, the higher at 18 mg per day. After 24 weeks 29 to 32 percent had a clinical benefit (response or stable disease). Serious side effects caused by the drug occurred in 8 and 16 percent, mainly raised liver enzymes, too much calcium in the blood and fatigue.
Are trials still running?
Yes. As of 26 October 2026 a phase 2 trial with 239 participants is running that tests weight and body function on semaglutide. A first trial on this with 168 participants is completed. Two phase 3 trials in lung cancer ended in 2013.
Võrdlused
Kuidas see võrdub
Seotud
Seotud tooted
MK-677 (Ibutamoren)
SARM-id ja rasvapõletajad · SARMs SARM-id ja rasvapõletajad · SARMs
1 suurus
LGD-4033 (Ligandrol)
SARM-id ja rasvapõletajad · SARMs SARM-id ja rasvapõletajad · SARMs
1 suurus
RAD-140 (Testolone)
SARM-id ja rasvapõletajad · SARMs SARM-id ja rasvapõletajad · SARMs
1 suurus
GW-501516 (Cardarine)
SARM-id ja rasvapõletajad · SARMs SARM-id ja rasvapõletajad · SARMs
1 suurus
Ostarine (MK-2866)

